Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
21.30
+0.30 (1.43%)
Jul 8, 2025, 10:39 AM GMT+1
-36.42%
Market Cap 28.23M
Revenue (ttm) n/a
Net Income (ttm) -2.83M
Shares Out 134.41M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,425
Average Volume 376,363
Open 20.71
Previous Close 21.00
Day's Range 20.48 - 22.00
52-Week Range 11.00 - 38.00
Beta -1.68
RSI 84.87
Earnings Date Jun 23, 2025

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.